Intellia Q2 net loss widens to $147M; NTLA-2002 Phase 2 meets endpoints, Phase 3 on track

Intellia Therapeutics, Inc.

2024-Q2 EPS reported -$2.64 revenue$35,892,000

NTLA-2002 Phase 2 for HAE met primary and all secondary endpoints; 50 mg dose selected for pivotal Phase 3, on track to start 2H 2024.
Phase 3 MAGNITUDE trial (NTLA-2001 for ATTR-CM) enrolling rapidly across >12 countries and >35 sites.
Plans to initiate Phase 3 of NTLA-2001 for ATTRv-PN by year-end and dose first patient in NTLA-3001 Phase 1/2 for AATD in 2H 2024.
Q2 2024 net loss $147.0M vs $123.7M YoY; cash $939.9M expected to fund operations into late 2026.
Appointed Edward Dulac as CFO effective July 22 and Brian Goff to board of directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.